Suppression of malignancy targeting cyclic AMP signal transducing proteins.
Cho-Chung
Y S
YS
National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
D015124:8-Bromo Cyclic Adenosine Monophosphate / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D002477:Cells; D000242:Cyclic AMP / Q000031:analogs & derivatives / Q000494:pharmacology / Q000502:physiology*; D005260:Female; D006801:Humans; D046911:Macromolecular Substances; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000473:pathology*; D016376:Oligonucleotides, Antisense / Q000494:pharmacology; D011494:Protein Kinases / Q000235:genetics; D012333:RNA, Messenger / Q000235:genetics; D011953:Receptors, Cyclic AMP / Q000502:physiology*; D015398:Signal Transduction
D000970:Antineoplastic Agents; D046911:Macromolecular Substances; D016376:Oligonucleotides, Antisense; D012333:RNA, Messenger; D011953:Receptors, Cyclic AMP; D015124:8-Bromo Cyclic Adenosine Monophosphate; C044258:8-chloro-cyclic adenosine monophosphate; D000242:Cyclic AMP; D011494:Protein Kinases